AU2018360827B2 - Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same - Google Patents

Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same Download PDF

Info

Publication number
AU2018360827B2
AU2018360827B2 AU2018360827A AU2018360827A AU2018360827B2 AU 2018360827 B2 AU2018360827 B2 AU 2018360827B2 AU 2018360827 A AU2018360827 A AU 2018360827A AU 2018360827 A AU2018360827 A AU 2018360827A AU 2018360827 B2 AU2018360827 B2 AU 2018360827B2
Authority
AU
Australia
Prior art keywords
compound
cocrystal
theta
formula
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2018360827A
Other languages
English (en)
Other versions
AU2018360827A1 (en
Inventor
Chong-Hui Gu
Benjamin S. Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2018360827A1 publication Critical patent/AU2018360827A1/en
Assigned to LES LABORATORIES SERVIER reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2018360827B2 publication Critical patent/AU2018360827B2/en
Priority to AU2024203186A priority Critical patent/AU2024203186B2/en
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Request to Amend Deed and Register Assignors: LES LABORATORIES SERVIER
Priority to AU2026205552A priority patent/AU2026205552A1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018360827A 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same Active 2039-09-11 AU2018360827B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024203186A AU2024203186B2 (en) 2017-11-02 2024-05-14 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
AU2026205552A AU2026205552A1 (en) 2017-11-02 2026-07-13 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203186A Division AU2024203186B2 (en) 2017-11-02 2024-05-14 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (2)

Publication Number Publication Date
AU2018360827A1 AU2018360827A1 (en) 2020-05-14
AU2018360827B2 true AU2018360827B2 (en) 2024-02-22

Family

ID=64572453

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018360827A Active 2039-09-11 AU2018360827B2 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
AU2024203186A Active AU2024203186B2 (en) 2017-11-02 2024-05-14 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
AU2026205552A Pending AU2026205552A1 (en) 2017-11-02 2026-07-13 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024203186A Active AU2024203186B2 (en) 2017-11-02 2024-05-14 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
AU2026205552A Pending AU2026205552A1 (en) 2017-11-02 2026-07-13 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Country Status (25)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101B1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (1) KR102731624B1 (enExample)
CN (2) CN118359585A (enExample)
AU (3) AU2018360827B2 (enExample)
CA (1) CA3081535A1 (enExample)
DK (1) DK3704101T3 (enExample)
EA (1) EA202091112A1 (enExample)
ES (1) ES3075257T3 (enExample)
FI (1) FI3704101T3 (enExample)
HR (1) HRP20260783T1 (enExample)
IL (2) IL274123B2 (enExample)
LT (1) LT3704101T (enExample)
MA (1) MA50526B1 (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
PT (1) PT3704101T (enExample)
RS (1) RS68236B1 (enExample)
SG (1) SG11202003612VA (enExample)
SI (1) SI3704101T1 (enExample)
SM (1) SMT202600262T1 (enExample)
TW (2) TWI796377B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
US20230346789A1 (en) * 2022-03-31 2023-11-02 Msd International Gmbh Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
CN121843929A (zh) * 2023-09-18 2026-04-10 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
US20250257050A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003640A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003640A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
MX2020004513A (es) 2020-09-17
BR112020008598A2 (pt) 2021-01-26
EP3704101B1 (en) 2026-05-06
CN111527076A (zh) 2020-08-11
IL274123B1 (en) 2023-09-01
IL305426B1 (en) 2024-06-01
MX2022014792A (es) 2023-01-16
JP7335877B2 (ja) 2023-08-30
HRP20260783T1 (hr) 2026-08-14
TWI796377B (zh) 2023-03-21
AU2026205552A1 (en) 2026-07-30
EP3704101A1 (en) 2020-09-09
KR102731624B1 (ko) 2024-11-19
US12679820B2 (en) 2026-07-14
CA3081535A1 (en) 2019-05-09
PT3704101T (pt) 2026-06-24
US11345677B2 (en) 2022-05-31
US20220363661A1 (en) 2022-11-17
CN111527076B (zh) 2024-03-12
FI3704101T3 (fi) 2026-06-12
UA127380C2 (uk) 2023-08-02
US11851417B2 (en) 2023-12-26
IL274123B2 (en) 2024-01-01
TW202337885A (zh) 2023-10-01
MA50526B1 (fr) 2026-06-30
AU2018360827A1 (en) 2020-05-14
JP2021501766A (ja) 2021-01-21
ES3075257T3 (en) 2026-07-29
IL305426A (en) 2023-10-01
SG11202003612VA (en) 2020-05-28
CN118359585A (zh) 2024-07-19
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
EA202091112A1 (ru) 2020-07-23
KR20240166601A (ko) 2024-11-26
US20240343705A1 (en) 2024-10-17
PH12020550462A1 (en) 2021-03-22
IL305426B2 (en) 2024-10-01
WO2019090059A1 (en) 2019-05-09
IL274123A (en) 2020-06-30
LT3704101T (lt) 2026-06-25
JP7780576B2 (ja) 2025-12-04
TW201930285A (zh) 2019-08-01
RS68236B1 (en) 2026-07-31
DK3704101T3 (da) 2026-06-15
AU2024203186A1 (en) 2024-05-30
JP2024113028A (ja) 2024-08-21
SI3704101T1 (sl) 2026-07-31
US20210198234A1 (en) 2021-07-01
JP7499377B2 (ja) 2024-06-13
AU2024203186B2 (en) 2026-04-16
SMT202600262T1 (it) 2026-07-16
TWI839131B (zh) 2024-04-11
KR20200095480A (ko) 2020-08-10

Similar Documents

Publication Publication Date Title
AU2024203186B2 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
US20240041892A1 (en) Therapeutically active compounds and their methods of use
US20250034109A1 (en) Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same
US20250041283A1 (en) Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same
BR112020008598B1 (pt) Cocristal, composição farmacêutica e usos de um cocristal ou de uma composição farmacêutica
EA042081B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA048730B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
AU2022219973A1 (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER NAME(S): LES LABORATORIES SERVIER

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: VORANIGO VORASIDENIB

Filing date: 20240911

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: VORANIGO VORASIDENIB

Filing date: 20240911

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: VORANIGO VORASIDENIB

Filing date: 20240911

Extension date: 20390911